TGTX TG Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why TGTX matters now
TG Therapeutics, Inc. (TGTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $57.12 with -3.28% on the session and $8.74B in market capitalization; recent performance reads 1-month +34.97% and YTD +78.53%.
The latest financial table shown here is Q1 2026, with revenue of $204.9M, net income of $19.8M, and EPS of $0.12. Investors can compare that operating picture with valuation signals such as P/E 11.92 and FCF yield -0.2%.
The latest indexable market news headline is "2 Fast-Growing Pharmaceutical Stocks to Buy Now" from Fool - Investing News.
Additional event context on this page matters because analyst consensus is Buy with a median target of $54.50; recent insider activity includes Charney Laurence N filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
11.92
PEG
0.01
P/B
13.18
P/S
11.63
EV/EBITDA
56.32
DCF Value
$-63.08
FCF Yield
-0.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
83.0%
Operating Margin
21.3%
Net Margin
66.0%
ROE
87.4%
ROA
30.2%
ROIC
11.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $204.9M | $19.8M | $0.12 |
| Q4 2025 | $192.6M | $23.0M | $0.14 |
| FY 2025 | $616.3M | $447.2M | $2.77 |
| Q3 2025 | $161.7M | $390.9M | $2.43 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$54.50
Target (Median)
$54.50
Target Range
$39.00 - $70.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.68
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.